|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0036043,
umls-concept:C0036337,
umls-concept:C0073393,
umls-concept:C0087111,
umls-concept:C0205265,
umls-concept:C0525045,
umls-concept:C0733511,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1555582,
umls-concept:C2603343
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2001-9-19
|
|
pubmed:abstractText |
An adequate therapy for psychotic disorders needs to be effective against mood as well as psychotic symptoms. Analyses of data from clinical trials of risperidone in schizophrenia and small open-label studies in mania suggest that risperidone may have this broad efficacy profile. We present data on a 6-week trial of risperidone for the treatment of schizoaffective disorder that was part of a larger, 6-month surveillance study of patients with affective disorders.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0160-6689
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
623-30
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11561935-Adult,
pubmed-meshheading:11561935-Anticonvulsants,
pubmed-meshheading:11561935-Antidepressive Agents,
pubmed-meshheading:11561935-Antipsychotic Agents,
pubmed-meshheading:11561935-Basal Ganglia Diseases,
pubmed-meshheading:11561935-Bipolar Disorder,
pubmed-meshheading:11561935-Drug Administration Schedule,
pubmed-meshheading:11561935-Female,
pubmed-meshheading:11561935-Humans,
pubmed-meshheading:11561935-Lithium,
pubmed-meshheading:11561935-Male,
pubmed-meshheading:11561935-Middle Aged,
pubmed-meshheading:11561935-Psychiatric Status Rating Scales,
pubmed-meshheading:11561935-Psychotic Disorders,
pubmed-meshheading:11561935-Risperidone,
pubmed-meshheading:11561935-Severity of Illness Index,
pubmed-meshheading:11561935-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
|
|
pubmed:affiliation |
Hospital Clinic, University of Barcelona, Spain. EVIETA@clinic.ub.es
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
